
Gary Blevins never smoked a day in his life. The 64-year-old Parma resident ran regularly and worked as a mechanical engineer, so when doctors told him he had stage 4 non-small cell lung cancer in both lungs, with the disease also found in one of his lymph nodes, it hit like a gut punch no one saw coming.
Blevins recalled that doctors initially described what looked like a raging infection in his right lung, according to FOX 8 News. That diagnosis soon changed course. “You have got non small cell cancer, and it's in both lungs, and they found it in one of the lymph nodes,” Blevins said, describing how doctors broke the news that the cancer had spread.
What came next changed the trajectory of his case. Genetic testing at Cleveland Clinic identified a specific mutation driving his cancer, one that doctors could target directly with a daily pill called Tagrisso, per the station's report. Blevins began feeling better within days of starting the medication, and his tumors started shrinking soon after.
How the Targeted Pill Works
Gary's physician, thoracic oncologist Dr. Lukas Delasos, explained that Tagrisso blocks a signal sent out by the mutated protein driving Blevins's cancer, effectively shutting down the cell machinery that fuels tumor growth, the same account notes. Blevins now takes his medications daily, a routine that has become part of his new normal.
Not every lung cancer patient qualifies for this kind of treatment. Doctors say biomarker testing is what makes the difference, helping identify which patients may actually benefit from a targeted approach rather than standard chemotherapy, per the same report. The National Comprehensive Cancer Network states that treatment of metastatic non-small cell lung cancer is based on features of the cancer, a patient's overall health, and their goals for treatment, and the organization recommends biomarker testing for driver mutations in adenocarcinoma, large cell carcinoma and rare cell types. Among its preferred therapies for lung cancers carrying an EGFR exon 19 deletion or EGFR L858R mutation, the NCCN lists osimertinib, the generic name for Tagrisso.
A Mutation More Common in Nonsmokers
Blevins's status as a lifelong nonsmoker is notable given what's known about this category of mutations. The American Lung Association notes that patients with EGFR-mutated lung cancers typically have minimal to no smoking history, though the group does not say these mutations occur exclusively in nonsmokers. It's a pattern that underscores why doctors are urging anyone with a persistent cough or shortness of breath to get it checked, regardless of smoking history.
That testing gap is part of a broader national picture. A nationwide retrospective analysis of more than 42,000 patients with metastatic non-small cell lung cancer, conducted between January 2011 and April 2023, found that 82.1 percent received at least one biomarker test, according to research published in the Journal of Clinical Oncology Precision Oncology. Testing rates climbed over time, with the highest reported 2023 rates seen for EGFR and ALK mutations, though the study's authors cautioned that gaps and potential disparities remain tied to factors like insurance type, race and smoking status.
A separate prospective study conducted at 18 U.S. community practices between 2020 and 2022 found that 98.8 percent of patients eventually received testing for at least one biomarker, but only 79.0 percent had a test result in hand before starting first-line therapy. Among patients with an actionable mutation who did have results before treatment began, 77.7 percent went on to receive first-line targeted therapy, the same journal reported, concluding that guideline-compliant testing rates still fall short of recommendations despite improvement over earlier data.
Building a New Life Alongside Treatment
While managing his diagnosis, Blevins has kept moving forward with his personal life. He married his longtime love, Betty, on Valentine's Day earlier this year, and the newlyweds are now planning a scuba-diving trip to Honduras for the holiday season, per the station's account.
Blevins's story echoes a broader trend reshaping treatment for driver-mutation lung cancers. An ASCO living guideline update tied to 2024 reported seven new regulatory approvals and changes to first-line therapy for some of these mutations, reflecting how quickly the targeted-therapy landscape continues to shift. Elsewhere, NPR reported on Stanford professor Bryant Lin, who was diagnosed with stage IV lung cancer and began taking daily Tagrisso in May 2024, only to see the targeted therapy stop working about a year into treatment — a reminder that responses to these drugs can vary over time.
For now, Blevins's tumors are shrinking and his energy is returning. Doctors stress that his case illustrates why biomarker testing matters, and why a persistent cough or shortness of breath should never be dismissed, even in someone who has never touched a cigarette.









